Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Meta-Analysis
. 2010 Feb 14;16(6):770-7.
doi: 10.3748/wjg.v16.i6.770.

Treatment of hepatitis B virus-associated glomerulonephritis: a meta-analysis

Yu Zhang  1 , Jian-Hua Zhou, Xiao-Ling Yin, Feng-Yu Wang
Affiliations
Meta-Analysis

Treatment of hepatitis B virus-associated glomerulonephritis: a meta-analysis

Yu Zhang et al. World J Gastroenterol. .

Abstract

Aim: To evaluate the efficacy of antiviral or corticosteroid treatment on hepatitis B virus-associated glomerulonephritis (HBV-GN).

Methods: Six and five trials were used respectively to evaluate the efficacy of either antiviral or corticosteroid treatment on HBV-GN. Pediatric patients were pooled separately to assess their response to the above treatment modalities. The primary and secondary outcomes were remission of proteinuria and clearance of Hepatitis B e-antigen (HBeAg), respectively. A fixed or random effect model was established to collect the data.

Results: The remission rate of proteinuria (RR = 1.69, 95% CI: 1.08-2.65) and the clearance rate of HBeAg (RR = 6.44, 95% CI: 3.11-13.35) were significantly higher in antiviral treatment group than in control group. The proteinuria remission was significantly associated with HBeAg clearance (P = 0.002). However, the difference in proteinuria remission rate was not statistically significant between corticosteroid treatment group and control group (RR = 1.45, 95% CI: 0.68-3.11). Antiviral therapy could significantly promote the HBeAg clearance in pediatric patients, but neither antiviral nor corticosteroid therapy could significantly decrease proteinuria in pediatric patients compared to controls.

Conclusion: Antiviral but not corticosteroid treatment can decrease proteinuria and promote HBeAg clearance in HBV-GN patients.

PubMed Disclaimer

Figures

Figure 1
Figure 1
Proteinuria remission rate in antiviral treatment group and control group (A, B) and in pediatric patients (C).
Figure 2
Figure 2
Clearance rate of HBeAg in antiviral treatment group and control group (A) and in pediatric patients (B).
Figure 3
Figure 3
Proteinuria remission rate in corticosteroid treatment group and control group (A) and in pediatric patients (B).
Figure 4
Figure 4
Funnel plots for 6 articles in meta-analysis of clinical response to antiviral therapy (A), 6 articles in meta-analysis of virologic response to antiviral therapy (B), and 5 articles in meta-analysis of clinical response to corticosteroid treatment (C).
See this image and copyright information in PMC

References

    1. Bhimma R, Coovadia HM, Adhikari M, Connolly CA. The impact of the hepatitis B virus vaccine on the incidence of hepatitis B virus-associated membranous nephropathy. Arch Pediatr Adolesc Med. 2003;157:1025–1030. - PubMed
    1. Xu H, Sun L, Zhou LJ, Fang LJ, Sheng FY, Guo YQ. The effect of hepatitis B vaccination on the incidence of childhood HBV-associated nephritis. Pediatr Nephrol. 2003;18:1216–1219. - PubMed
    1. Walters S, Levin M. Infectious diseases and the kidney. In: Barratt TM, Avner ED, Harmon WE, editors. Pediatric Nephrology. 4th ed. Philadelphia, PA: Lippincott Williams & Wilkins; 1999. pp. 1088–1090.
    1. Lai KN, Lai FM, Chan KW, Chow CB, Tong KL, Vallance-Owen J. The clinico-pathologic features of hepatitis B virus-associated glomerulonephritis. Q J Med. 1987;63:323–333. - PubMed
    1. Gilbert RD, Wiggelinkhuizen J. The clinical course of hepatitis B virus-associated nephropathy. Pediatr Nephrol. 1994;8:11–14. - PubMed

Publication types

MeSH terms

LinkOut - more resources